Hibiya Mitsui Tower
12 floor WORK STYLING 1-1-2 Yurakucho Chiyoda-ku
Tokyo 100-0006
Japan
https://www.healios.co.jp
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Tadahisa S. Kagimoto M.D. | Chairman & CEO | N/A | N/A | 1976 |
Mr. Richard P. Kincaid | CFO, Executive Officer & Internal Director | N/A | N/A | 1976 |
Mr. Masanori Sawada M.D., MBA, Ph.D. | Executive VP, Chief Medical Officer and In Charge of Development & Human Resources & General Affairs | N/A | N/A | 1981 |
Mr. Kouichi Tamura Ph.D. | Exec. Off., Chief Scientific Off., In Charge of Res. & Manufacturing and Head of Kobe Res. Institute | N/A | N/A | 1956 |
Mr. Yoshinari Matsuda | Managing Director | N/A | N/A | 1978 |
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
Healios K.K.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.